Welcome to our dedicated page for PLUS THERAPEUTICS news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on PLUS THERAPEUTICS stock.
Plus Therapeutics reports news on its CNS oncology business, which combines precision diagnostics with targeted radiopharmaceutical development for central nervous system cancers. Recurring updates cover REYOBIQ™ (rhenium Re186 obisbemeda), a radiotherapeutic program for indications including leptomeningeal metastases and recurrent glioblastoma, as well as clinical and translational presentations, regulatory designations, manufacturing technology transfer and supply-chain partnerships.
The company’s news also covers the commercial expansion of CNSide®, including payer coverage, Medicare enrollment and reimbursement work for its cerebrospinal fluid assay platform. Corporate updates include leadership appointments, equity inducement grants under Nasdaq rules, financial results, capital actions and listing-compliance matters tied to its Nasdaq-traded common stock.
Plus Therapeutics (Nasdaq: PSTV) appointed diagnostics veteran Ron Andrews to its Board of Directors on March 26, 2026. Andrews brings over 35 years in diagnostics, experience leading Abbott, Roche, Thermo Fisher units and public startups, and has been involved in >$600M capitalization and ~$15B in exits.
He will support scaling CNSide, a cerebrospinal-fluid diagnostic for leptomeningeal metastases, and advise strategy, fundraising and commercialization efforts for the company’s diagnostics business.
Plus Therapeutics (Nasdaq: PSTV) will present a health economics analysis at ISPOR 2026 showing the CNSide CSF assay could cut leptomeningeal metastases (LM) healthcare costs by ~40% (range 33%–47%).
Key figures: median inpatient admissions ~$20,000 (IQR $10,000–$30,000) and LM costs may exceed $100,000 per month; findings support U.S. commercialization efforts.
Plus Therapeutics (Nasdaq: PSTV) reported full-year 2025 results and provided 2026 milestones for REYOBIQ clinical programs and CNSide commercial rollout. Key highlights include a $15 million upsized public offering, $13.1 million cash and investments at year-end, CPT Category III reimbursement for convection-enhanced delivery, and expanded CNSide lab licensing to 49 states.
The company expects REYOBIQ ReSPECT-LM data in Q3 2026, ReSPECT-GBM data in Q4 2026, increased 2026 R&D and G&A spend, and targets >150 million payer coverage and Medicare pathway for CNSide.
Plus Therapeutics (NASDAQ: PSTV) announced the AMA CPT Editorial Panel approved a new Category III CPT code X566T to track convection-enhanced delivery (CED) used with REYOBIQ for recurrent glioblastoma and pediatric brain cancer. The code will be published July 1, 2026 and effective for reporting January 1, 2027.
The company said the code enables standardized utilization tracking, may inform future coverage and reimbursement, and supports REYOBIQ commercialization while Plus advances clinical enrollment milestones in 2026.
Plus Therapeutics (NASDAQ: PSTV) provided a business update on REYOBIQ clinical progress and U.S. commercialization of CNSide, announcing an upsized $15 million offering to fund 2026 priorities and extend cash runway through 2027. Key 2026 milestones include REYOBIQ dose optimization and data in Q3 2026, ReSPECT-GBM data and FDA end-of-phase alignment in Q4 2026, commercial manufacturing scale-up, and ReSPECT-PBC Phase 1 enrollment. CNSide targets include coverage for 150 million US lives, Medicare/Medicaid coverage, >1,250 tests/year, and launch of additional CSF tumor characterization tests. A conference call and webcast are scheduled for January 22, 2026 at 9:00 a.m. ET.
Plus Therapeutics (NASDAQ: PSTV) will provide a business update on Thursday, January 22, 2026 before the market opens and host a conference call and webcast at 9:00 AM ET. Management will discuss recent developments and provide additional details.
Webcast and dial-in information: webcast URL available, participant dial-in 1-888-349-0106 (please dial in 15 minutes early). A replay will be available on the company website for 90 days after the live call.
Plus Therapeutics (NASDAQ: PSTV) priced an upsized underwritten public offering of 39,473,684 units at $0.38 per unit, producing expected gross proceeds of approximately $15 million before underwriting discounts, commissions and expenses. Each unit includes one share of common stock and one warrant exercisable immediately at $0.38 per share and expiring five years from issuance.
The underwriter has a 30‑day option to purchase up to an additional 5,921,052 shares and/or warrants to cover over‑allotments. Proceeds are intended for working capital and general corporate purposes. The offering is expected to close on January 15, 2026, subject to customary closing conditions; Lake Street Capital Markets is sole underwriter. Registration statements were declared effective January 13, 2026.
Plus Therapeutics (NASDAQ:PSTV) completed a Type B meeting with the FDA on Jan 8, 2026 to discuss a potential pivotal trial strategy for REYOBIQ in leptomeningeal metastases (LM).
The FDA indicated accelerated approval may be appropriate for LM but said circulating tumor cells (CTCs) lack sufficient data to serve as an intermediate clinical endpoint. The agency recommended a primary endpoint with established clinical benefit (for example, overall survival), discussed randomized controlled trial designs including an intrathecal chemotherapeutic comparator, and said multiple histologies may be reasonable in one trial. Plus plans to incorporate FDA feedback into its dose‑optimization trial, seek protocol alignment later in 2026, and accelerate manufacturing scale‑up to target pivotal trial readiness in late 2026.
Plus Therapeutics (Nasdaq: PSTV) announced that CNSide Diagnostics, its wholly owned subsidiary, has received state lab licenses to provide the CNSide® CSF Tumor Cell Enumeration (TCE) laboratory-developed test in California, Rhode Island and Maryland, bringing coverage to 48 of 50 U.S. states and serving over 90% of the U.S. population.
The CNSide® CSF assay supports diagnosis and treatment monitoring for leptomeningeal metastases, reports >11,000 tests at 120+ U.S. cancer institutions since 2020, and cites 92% sensitivity, 95% specificity, and influence on treatment decisions in 90% of cases. Tests are performed at a CLIA-certified facility in Houston and are available exclusively through CNSide Diagnostics.
Plus Therapeutics (Nasdaq: PSTV) announced two hires for its wholly owned subsidiary CNSide Diagnostics and the issuance of inducement equity grants on December 4, 2025. The company said it is scaling lab operations to address a stated $6 billion+ U.S. addressable market for a cerebrospinal fluid assay for metastatic CNS cancers and plans additional payor agreements beyond UnitedHealthcare and Humana.
The hires: Prem Gurnani (Senior Director, Lab Operations) and Elaine Luckey (Director, Quality & Regulatory). Each received options to buy 33,750 shares and 11,250 RSUs with multi-year vesting; option exercise price equals the Dec 4, 2025 closing stock price. A Form S-8 was filed covering the awards.